SynthesisFrontiers in microbiology2026
Current advances in the epidemiology, risk factors, prevention, management, and long-term outcomes of herpes zoster and post-herpetic neuralgia.
Synthesis in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Herpes zoster (HZ) results from reactivation of latent varicella-zoster virus and is a major cause of morbidity, particularly among older adults and immunocompromised individuals. Post-herpetic neuralgia (PHN), the most common chronic complication of HZ, is characterized by persistent neuropathic pain that can substantially impair quality of life. Despite advances in antiviral therapy and vaccination, PHN remains a significant clinical challenge. This review presents current evidence on the epidemiology, risk factors, pathophysiology, clinical manifestations, prevention, and management of HZ and PHN, with emphasis on factors associated with PHN development and contemporary therapeutic approaches. Methods: A narrative review of the literature was conducted using publications indexed in PubMed, Scopus, Web of Science, and Google Scholar from January 2010 to June 2026. Peer-reviewed studies, systematic reviews, meta-analyses, randomized controlled trials, cohort studies, and clinical guidelines addressing HZ, PHN, and related management strategies were included. Findings were synthesized narratively. Results: Advanced age, severe acute zoster pain, extensive rash involvement, prodromal pain, and immunocompromised status were consistently identified as major predictors of PHN. Early initiation of antiviral therapy within 72 h of rash onset was associated with reduced acute disease severity and may decrease the risk of prolonged pain. Evidence supports the use of gabapentinoids, tricyclic antidepressants, topical lidocaine, and capsaicin for PHN management, while multidisciplinary approaches incorporating non-pharmacologic interventions may further improve outcomes. Recombinant zoster vaccination demonstrates high effectiveness in preventing HZ and PHN in older adults. Conclusion: PHN remains a substantial source of long-term morbidity following HZ, particularly in aging populations. Early recognition of high-risk patients, prompt antiviral treatment, evidence-based pain management, and wider uptake of recombinant zoster vaccination are key strategies for reducing disease burden and improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.